Agenda Revealed | 2025 WAIC Qiming Venture Partners Entrepreneurship and Investment Forum: Venture Capital Enters a Resonance Cycle of AI Technology and Applications
This sub-forum will showcase and explore the latest breakthroughs in AI technology and applications through the lens of innovation. Qiming Venture Partners will bring together leading scholars and pioneering entrepreneurs in the field — from both the startup and investment perspectives — for four keynote speeches and four panel discussions.
Qiming Venture Partners · Entrepreneurship and Investment Forum
Venture Capital Unlocks a Resonance Cycle of AI Technology and Applications
July 28 Morning at the World Artificial Intelligence Conference (WAIC)
Blue Hall, Shanghai World Expo Center!
This is a sub-forum showcasing and exploring the latest breakthroughs in AI technology and applications through an innovation lens.
From the perspectives of entrepreneurship and investment, we will join hands with leading scholars and pioneering founders in the field to bring you:
4 keynote speeches
4 panel discussions
Where is the next stop in the evolution of large model technology?
Are world models the critical path to AGI?
When will embodied AI achieve large-scale commercial deployment?
Is AI hardware a blue ocean market for Chinese entrepreneurs?
Can startups escape the "shadow of the giants"?
Which domains harbor the next wave of disruptive entrepreneurial opportunities?
Please scan the QR code below or click "Read More" at the end of this article
Log in and fill in your real-name information
Enter the forum interface
Select the July 28 "Qiming Venture Partners · Entrepreneurship and Investment Forum"
Click "Register for Offline Attendance" in the lower left corner to complete registration
Join us on-site to hear brilliant insights from our speakers!
PAST HIGHLIGHTS
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through mergers and acquisitions. More than 80 portfolio companies have become recognized unicorns or super-unicorns.
Many companies in Qiming Venture Partners' portfolio have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ: WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), Sinocelltech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.